Galmed Pharmaceuticals (GLMD)
(Real Time Quote from BATS)
$8.02 USD
-1.33 (-14.23%)
Updated Sep 24, 2024 12:06 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Galmed Pharmaceuticals Ltd. [GLMD]
Reports for Purchase
Showing records 1 - 20 ( 192 total )
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Latest ARMOR Open Label Data Show Aramchol''s Potential in NASH; Galmed''s Future Remains Uncertain; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
3Q Recap; Galmed''s Future Remains Uncertain; Search For Strategic Alternatives Continues; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
2Q Recap; Aramchol and Amilo-5MER Both in Holding Pattern; Search For Strategic Alternatives Continues; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Healthcare Coverage Update - Dropping Coverage
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
1Q Recap: In NASH Limbo, Galmed Restructures; Considers Other Anti-Fibrotic Indications Beyond NASH; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
4Q Recap; Phase 3 Portion of ARMOR Trial Delayed to 2H23;Downgrade to Neutral on Uncertainty and Lack of Catalysts
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Galmed Kicks Off 2022 With New Aramchol Patents and Positive Amilo-5MER Phase 1 Data
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
3Q Recap; Initial Open Label Data From ARMOR Encouraging, Given Its Small Sample Size; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Publication Offers Mechanistic Rationale of Amilo-5MER''s Development For Chronic Inflammatory Diseases
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
2Q21 Results; Active 12 Months Ahead; Full Phase 2 Acne Data Expected in October
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
2Q21 Recap: ARMOR Open Label Readout on Target in 4Q21 Ahead of Registrational Phase 3 Portion
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
FDA Agrees with Plan to Use Aramchol Meglumine in Phase 3 ARMOR Study; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
1Q21 Recap; Expecting Open Label Data in 4Q21 to Inform Treatment Duration in Pivotal ARMOR; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
IND Approval in China a Key Step in Establishing ARMOR as a Global, Pivotal NASH Study; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
ARMOR Resets to Incorporate Aramchol Meglumine in Phase 3; Moderate PT to $25 on Adjusted Clinical Timeline
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
First-in-Human Phase 1 Trial of Amilo-5MER Underway as Galmed Eyes Development for IBD; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
3Q20 Recap: ARMOR Enrollment Struggles; December Milestones for Aramchol Meglumine and Amilo-5MER
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Galmed Explores Potential of Bespoke Microbiome Treatment in Combination With Aramchol; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E